Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?
The Archer FusionPlex Lymphoma assay showed a somewhat lower detection rate of novel genetic subtypes compared to reports based on exome sequencing, yet identified novel genetic subtypes in over one-third of patients. However, an in-depth STRATOS statistical analysis did not confirm its predictive value for DLBCL prognosis, likely due to factors like patient selection and sample size limitations.
Authors
- Barbara Jezeršek Novaković (ORCID: https://orcid.org/0000-0002-5063-7072)
- Vita Šetrajčič Dragoš (ORCID: https://orcid.org/0000-0002-7902-8879)
- Milica Miljković (ORCID: https://orcid.org/0000-0002-3929-4697)
- Srdjan Novaković (ORCID: https://orcid.org/0000-0002-8888-4810)
- Lučka Boltežar (ORCID: https://orcid.org/0000-0001-7280-1470)
- Gorana Gašljević (ORCID: https://orcid.org/0000-0002-8332-3627)
Institutions
- University of Ljubljana (SI)
- Institute of Oncology Ljubljana (SI)
- University of Maribor (SI)
Publication Details
- Journal
- Radiology and Oncology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.2478/raon-2025-0028
- Citations
- 2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Javna Agencija za Raziskovalno Dejavnost RS